Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-06-12
2007-06-12
Le, Long V. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007920, C435S007930, C435S007940, C436S071000, C436S501000, C436S518000
Reexamination Certificate
active
10802643
ABSTRACT:
Immunoassays for malondialdehyde-modified low density lipoprotein (MDA-modified LDL) and oxidized low density lipoprotein (OxLDL), monoclonal antibodies (and the cell lines for them) for use in the assays, and a storage-stable standard (which may be used as a calibrator and/or control) are disclosed. MDA-modified LDL and OxLDL are implicated in atherosclerosis and its etiology.
REFERENCES:
patent: 5024829 (1991-06-01), Berger et al.
patent: 5026537 (1991-06-01), Daddona et al.
patent: 5046499 (1991-09-01), Berger
patent: 5120834 (1992-06-01), Gargan et al.
patent: 5196324 (1993-03-01), Bumol et al.
patent: 5223410 (1993-06-01), Gargan et al.
patent: 5362649 (1994-11-01), Schwertner
patent: 5380667 (1995-01-01), Schwertner
patent: 5396886 (1995-03-01), Cuypers
patent: 5453359 (1995-09-01), Gargan et al.
patent: 5487892 (1996-01-01), Gargan
patent: 5597726 (1997-01-01), Bumol et al.
patent: 5604105 (1997-02-01), Jackowski
patent: 5658729 (1997-08-01), Hayden et al.
patent: 5690103 (1997-11-01), Groth et al.
patent: 5710008 (1998-01-01), Jackowski
patent: 5731208 (1998-03-01), Henicke
patent: 5756067 (1998-05-01), Redgrave et al.
patent: 6040147 (2000-03-01), Ridker et al.
patent: 6309888 (2001-10-01), Holvoet
patent: 6727102 (2004-04-01), Holvoet et al.
patent: 2003/0100486 (2003-05-01), Ridker
patent: 2003/0152566 (2003-08-01), Schonbeck et al.
patent: 0 327 418 (1989-08-01), None
patent: 0 484 863 (1992-05-01), None
patent: 0 433 088 (1997-06-01), None
patent: 4-173096 (1992-06-01), None
patent: 8-304395 (1996-11-01), None
patent: 9-5323 (1997-10-01), None
patent: WO 94/23302 (1994-10-01), None
patent: WO 98/59248 (1998-12-01), None
patent: WO 00/14548 (2000-03-01), None
Schier et al. (Journal of Molecular Biology, 1996, 263, pp. 551-567).
Liu et al. (American Heart Journal, 1992, 123(2), pp. 285-290).
Haberland et al. (Proceedings of the National Academy of Science, USA, vol. 79, Mar. 1982, pp. 1712-1716).
Palinski et al. (Journal of Clinical Investigation, vol. 98, No. 3, Aug. 1996, pp. 800-814).
Winzor et al. (Journal of Chromatography, 492, 1989, pp. 377-430).
Kotani et al. (Biochimica et Biophysica Acta, 1215, 1994, pp. 121-125).
Griffin et al. (Diabetic Medicine, 1997, 14, 741-747).
Adams JE, 3d, Bodor GS, Davila-Roman VG, Delmez JA, Apple FS, Ladenson JH, Jaffe AS. “Cardiac Troponin I. A Marker With High Specificity For Cardiac Injury,”Circulation1993; 88(1): 101-106.
American Biogenetic Sciences Inc.1995 Annual Report.24 pages (1995).
American Biogenetic Sciences. Focus on Diagnostic Tests: A Technology Analysis. Updated Full Report.33 pages. Paisley and Habermas, Inc. (Jun. 3, 1996).
American Biogenetic Sciences, Inc., “Renal dialysis joint venture announced by American Biogenetic Sciences, Inc. and Gull Laboratories, Inc.” News Release (Sep. 26, 1996).
American Biogenetic Sciences, Inc. Jesup & Lamont Securities Corporation, “New Buy Recommendation dated Mar. 28, 1996” (12 pages.).
Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E. “Cardiac-Specific Troponin I Levels To Predict The Risk Of Mortality In Patients With Acute Coronary Syndromes.”N. Eng. J. Med.1996; 335(18): 1342-1349.
AtheroGenics, Inc. Printout of Web Site (WWW.ATHEROGENICS.COM). Home page and “Technology Platform” and “In The News” sections. 17 pages (printed June, 8, 1998).
Aviram M, Maor I. “Phospholipase D-Modified Low Density Lipoprotein Is Taken Up By Macrophages At Increased Rate. A Possible Role For Phosphatidic Acid.”J. Clin. Invest.1993; 91: 1942-1952.
Berliner JA, Heinecke JW. “The Role Of Oxidized Lipoproteins In Atherogenesis,”Free Radical Biology&Medicine1996; 20(5): 707-727.
Boyd H, Gown AM, Wolfbauer G, Chait A. “Direct Evidence For A Protein Recognized By A Monoclonal Antibody Against Oxidatively Modified LDL In Atherosclerotic Lesions From A Watanabe Hyperlipidemic Rabbit.”Am. J. Pathol.Nov. 1989; 135 (5): 815-825.
Brody, JE. “Hunt For Heart Disease Tracks A New Suspect.”The New York Times.3 pages (Jan. 6, 2004).
Brown MS, Goldstein JL. “Lipoprotein Metabolism In The Macrophage: Implications For Cholesterol Deposition In Atherosclerosis.”Annu. Review Biochem.1983; 52: 223-261.
Cartier R, Dagenais F, Hollmann C, Cambron H, Buluran J. “Chronic Exposure To Cyclosporin Affects Endothelial And Smooth Muscle Reactivity In The Rat Aorta.”Ann. Thorac. Surg.1994; 58: 789-794.
Chapelle JP. “How Should We proceed When A Myocardial Infarction Is Suspected,”Acta Clinica Belgica1984; 39(6): 393-395.
Chen CH, Nguyen HH, Weilbaecher D, Luo S, Gotto Jr. AM, Henry PD. “Basic Fibroblast Growth Factor Reverses Atherosclerotic Impairment Of Human Coronary Angiogenesis-Like Responses In Vitro.”Atherosclerosis1995; 116: 261-268.
Chin JH, Azhar S, Hoffman BB. “Inactivation Of Endothelial Derived Relaxing Factor By Oxidized Lipoproteins.”J. Clin. Invest.1992; 89: 10-18.
Cockcroft DW, Gault MH. “Prediction of creatinine clearance from serum creatinine.”Nephron1976; 16: 31-41.
Crisp SJ, Dunn JM, Rose ML, Barbir M, Yacoub MH. “Antiendothelial Antibodies After Heart Transplantation: The Accelerating Factor In Transplant-Associated Coronary Artery Disease?”J. Heart Lung Transplant.1994; 13(1, Part 1): 81-92.
Declerck PJ, Mombaerts P, Holvoet P, De Mol M, Collen D. “Fibrinolytic Response And Fibrin Fragment D-Dimer Levels In Patients With Deep Vein Thrombosis.”Thromb. Haemost.1987; 58(4): 1024-1029.
Degoulet P, Legrain M, Reach I, Aime F, Devries C, Rojas P, Jacobs C. “Mortality Risk Factors In Patients Treated By Chronic Hemodialysis.”Nephron1982; 31: 103-110.
Esterbauer H, Jurgens G, Quehenberger Q, Koller E. “Autooxidation Of Human Low Density Lipoprotein: Loss Of Polyunsaturated Fatty Acids And Vitamin E And Generation Of Aldehydes.”J. Lipid Res.1987; 28: 495-509.
Farber HW, Barnett HF. “Differences In Prostaglandin Metabolism In Cultured Aortic And Pulmonary Arterial Endothelial Cells Exposed To Acute and Chronic Hypoxia.”Circ. Res.1991; 68(5): 1446-1457.
Fogelman MA, Shechter I, Seager J, Hokom M, Child JS, Edwards PA. “Malondialdehyde Alteration Of Low Density Lipoproteins Leads To Cholesteryl Ester Accumulation In Human Monocyte-Macrophages.”Proc. Natl. Acad. Sci. USA1980; 77(4): 2214-2218.
Folcik VA, Nivar-Aristy RA, Krajewski LP, Cathcart MK. “Lipoxygenase Contributes To The Oxidation Of Lipids In Human Atherosclerotic Plaques.”J. Clin. Invest.1995; 96: 504-510.
Friedman JA, Dwyer JT. “Hyperhomocysteinemia As A Risk Factor For Cardiovascular Disease In Patients Undergoing Hemodialysis.”Nutr. Rev.1995; 53(7): 197-201.
Galle J, Bengen J, Schollmeyer P, Wanner C. “Oxidized Lipoprotein (A) Inhibits Endothelium-Dependent Dilation: Prevention By High Density Lipoprotein.”Eur. J. Pharmacol.1994; 265: 111-115.
Galle J, Schollmeyer P, Wanner C. “Cyclosporin And Oxidized Low Density Lipoproteins Synergistically Potentiate Vasoconstriction: Influence Of The Endothelium.”Eur. Heart J.1993; 14(Suppl. I): 111-117.
Gerrity RG. “The Role Of The Monocyte In Atherogenesis. I. Transition Of Blood-Borne Monocytes Into Foam Cells In Fatty Lesions.”Am. J. Pathol.1981; 103(2): 181-190.
Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. “Cytomegalovirus Infection Is Associated With Cardiac Allograft Rejection And Atherosclerosis.”J. Am. Med. Assoc.1989; 261(24): 3561-3566.
Haberland ME, Fogelman AM, Edwards PA. “Specificity Of Receptor-Mediated Recognition Of Malondialdehyde-Modified Low Density Lipoproteins.”Proc. Natl. Acad. Sci USA.1982; 79: 1712-1716.
Haberland ME, Olch CL, Fogelman AM. “Role Of Lysines In Mediating Interaction Of Modified Low Density Lipoproteins With The Scavenger Receptor Of Human Monocy
Collen Désiré José
Holvoet Paul Noel
Bryan Cave LLP
Cook Lisa V.
Gilbert Stephen P.
Le Long V.
Leuven Research & Development VZW
LandOfFree
Assays, antibodies, and standards for detection of oxidized... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assays, antibodies, and standards for detection of oxidized..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assays, antibodies, and standards for detection of oxidized... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3855951